At the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
During the NCCN Annual Conference, Ron Kline, MD, FAAP, from CMS’s Innovation Center, discussed the Center’s pilot Oncology Care Model.
Triple-negative breast cancer treatments being investigated include checkpoint inhibitors, agents that target the androgen receptor pathways, and antibody-drug conjugates.
At the NCCN Annual Conference in Orlando, Dr. April Salama discussed targeted treatment options in first- and second-line therapy for advanced melanoma.
First- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando.
During the NCCN Annual Conference in Orlando, Dr. Peter Carroll from UCSF discussed the evolution of screening tests for prostate cancer.
PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.